The aim of this study is to test if alkali treatment will preserve kidney graft function and
diminish the progression of chronic kidney disease in renal transplant patients. Additionally
the underlying mechanisms of nephrotoxicity of metabolic acidosis will be investigated in
this cohort.
This study is a multi-center, prospective, randomized, single-blind (patient),
placebo-controlled interventional trial to test the superiority of alkali treatment in
comparison to placebo on preservation of kidney function in 300 kidney transplant recipients.
The duration of the study will be 2 years for the individual participant. The patients will
be randomized into 2 arms: intervention arm (sodium hydrogen carbonate, product:
Nephrotrans®) and placebo arm (placebo comparator).
Several studies in CKD (chronic kidney disease) patients have shown that alkali therapy slows
progression of CKD.